Ignite Creation Date:
2024-05-05 @ 11:50 AM
Last Modification Date:
2024-10-26 @ 9:14 AM
Study NCT ID:
NCT00144859
Status:
COMPLETED
Last Update Posted:
2012-06-04
First Post:
2005-09-01
Brief Title:
Safety And Anti-Inflammatory Effect Of SB681323 In Patients With Chronic Obstructive Pulmonary Disease COPD
Sponsor:
GlaxoSmithKline
Organization:
GlaxoSmithKline
Study Overview
Official Title:
A 28-day Randomised Double-blind Placebo-controlled Study to Assess the Safety Tolerability Anti-inflammatory Effect and Steady-state Pharmacokinetics of SB-681323 75 mg Per Day in Patients With Chronic Obstructive Pulmonary Disease
Status:
COMPLETED
Status Verified Date:
2011-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a 28-day placebo controlled clinical study assessing the safety tolerability anti-inflammatory effect and pharmacokinetics of SB681323 in patients with COPD Chronic Obstructive Pulmonary Disease
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None